跳至主要内容
临床试验/ACTRN12623000297628
ACTRN12623000297628已完成4 期

Investigating the role of mainstream Pharmacological agents in the Regulation of the Optical Properties of the in vivo human ocular Lens (PROPeL) study

The University of Auckland0 个研究点目标入组 19 人开始时间: 2023年3月17日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
19

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Prevention
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 55 Years(—)
性别
All

入选标准

  • Healthy adults who are willing and able to provide written informed consent for study participation.

排除标准

  • - Significant refractive error, defined as over 6 Dioptres of myopic or hyperopic mean sphere refractive error
  • - History of ocular pathology or intraocular surgery that has the potential to affect the participant’s vision at the time of study participation
  • - A personal or family history of epilepsy or seizures, neurological disorders/ disease, or serious head injury and/or skull fracture, as these may affect performance in MRI procedures involving viewing flickering visual patterns (e.g. epilepsy) and/or lying still for an extended period of time (e.g. claustrophobia)
  • - Having metal implants (e.g. a cardiac pacemaker) or other contraindications that would put the safety of the participant at risk when undergoing an MRI scan
  • - Pregnant or breastfeeding women, as safety of the eye drops used in this study has not been established for use in pregnancy and lactation. For this reason, participants who become pregnant during the study will also not be able to continue participation.

研究者

相似试验